Table 1.

Effect of complexation or supplementation of cupric ions on antiproliferative activity of disulfiram

Treatment% Growth inhibition
HTB75 Ovarian CancerHTB77 Ovarian Cancer
Disulfiram (0.5 μmol/L)75 ± 481 ± 2
Disulfiram (0.5 μmol/L) + BCPS (200 μmol/L)0 ± 4*13 ± 5*
Disulfiram (0.1 μmol/L)12 ± 45 ± 2
Disulfiram (0.1 μmol/L) + CuSO4 (0.8 μmol/L)75 ± 2*83 ± 1*
520 Squamous Lung Cancer596 Adenosquamous Lung Cancer
Disulfiram (0.5 μmol/L)76 ± 369 ± 2
Disulfiram (0.5 μmol/L) + BCPS (200 μmol/L)0 ± 2*5 ± 6*
Disulfiram (0.25 μmol/L)66 ± 253 ± 4
Disulfiram (0.25 μmol/L) + CuSO4 (0.8 μmol/L)88 ± 291 ± 1*
  • NOTE: Cells stimulated with 10% FBS were plated at a density of 50,000 cells per well, and DMSO vehicle (5 μL/mL) or disulfiram was added to wells at the indicated concentrations. To decrease the concentration of available Cu2+, the impermeate Cu2+ chelator BCPS was added to medium. To increase the available Cu2+, medium was supplemented with CuSO4. After 48 hours, proliferation was quantitated by assessing the cell number–dependent reduction of the soluble yellow tetrazolium dye 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide to its insoluble formazan, measured as the absorbance at 540 nm.

  • * P < 0.001 versus respective disulfiram concentration alone.

  • P < 0.01 versus respective disulfiram concentration alone.